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Abstract: Germline mutations in the tumor suppressor gene PTEN cause PTEN Hamartoma Tumor
Syndrome (PHTS). Pediatric patients with PHTS frequently develop lipomas. Treatment attempts
with the mTORC1 inhibitor rapamycin were unable to reverse lipoma growth. Recently, lipomas
associated with PIK3CA-related overgrowth syndrome were successfully treated with the novel PI3K
inhibitor alpelisib. Here, we tested whether alpelisib has growth-restrictive effects and induces cell death
in lipoma cells. We used PTEN-haploinsufficient lipoma cells from three patients and treated them
with alpelisib alone or in combination with rapamycin. We tested the effect of alpelisib on viability,
proliferation, cell death, induction of senescence, adipocyte differentiation, and signaling at 1–100 µM
alpelisib. Alpelisib alone or in combination with rapamycin reduced proliferation in a concentration-
and time-dependent manner. No cell death but an induction of senescence was detected after alpelisib
incubation for 72 h. Alpelisib treatment led to a reduced phosphorylation of AKT, mTOR, and ribosomal
protein S6. Rapamycin treatment alone led to increased AKT phosphorylation. This effect could be
reversed by combining rapamycin with alpelisib. Alpelisib reduced the size of lipoma spheroids by
attenuating adipocyte differentiation. Since alpelisib was well tolerated in first clinical trials, this drug
alone or in combination with rapamycin is a potential new treatment option for PHTS-related adipose
tissue overgrowth.
Keywords: mTOR; AKT; PHTS; PROS; lipoma; rapamycin; overgrowth; proliferation; spheroids;
ribosomal protein S6
1. Introduction
Patients with germline mutations in the tumor suppressor gene PTEN show a wide variety
of phenotypes related to cellular overgrowth. There are several syndromes associated with
PTEN mutations, including Cowden syndrome, Proteus syndrome, and Bannayan–Riley–Ruvalcaba
syndrome (BRRS), all subsumed under the term PTEN Hamartoma Tumor Syndrome (PHTS) [1].
Symptoms include an increased risk for cancer (breast, endometrial, thyroid), macrocephaly, vascular
malformations, polyps of the gastrointestinal tract and other hamartomas, and, especially in the BRRS
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type, early-onset lipoma development [2]. Lipomatosis in pediatric patients can be life-threatening,
as the infiltrating growth of lipomatous masses can obstruct vital organ function and can lead to chronic
pain conditions. In some patients, resection as the only current treatment option is impossible due to
lipoma position or poor general condition of the patient. Treatment attempts with the mechanistic
target of rapamycin complex 1 (mTORC1) inhibitor rapamycin were shown to improve the general
condition of PHTS patients [3,4], but could not reverse lipoma growth [4]. PTEN antagonizes the
phosphoinositide-3-kinase (PI3K)/AKT/mTOR signaling pathway which regulates cellular metabolism
and promotes cellular growth, proliferation, and survival [5]. PI3K lies downstream of several growth
factor receptors and upon activation catalyzes the reaction of phosphatidylinositol (4,5)-bisphosphate
(PIP2) to phosphatidylinositol (3,4,5)-trisphosphate (PIP3). PIP3 is the key molecule to activate
further downstream signaling components, e.g., the pro-survival molecule AKT. PTEN acts as a lipid
phosphatase on PIP3, catalyzing the conversion to PIP2, and therefore is a negative regulator of the
AKT/mTOR signaling cascade [6]. mTORC1 regulates AKT activity through a negative feedback loop
via its target ribosomal protein S6 kinase. An inhibition of mTORC1 by rapamycin leads to an increased
activation of AKT [7]. This loss of negative feedback inhibition of AKT might be a cause for the reduced
efficacy of rapamycin observed in a treatment attempt of a child with PHTS-associated lipoma [4].
Recently, patients with lipomatous tumors associated with a related spectrum of syndromes
caused by mosaic activating PI3K mutations (PIK3CA-related overgrowth syndrome, PROS) were
successfully treated with the novel PI3K inhibitor alpelisib (BYL-719) [8]. The size of patients’ tumors
was reduced after few months and side effects were reported to be manageable. Alpelisib is a selective
PI3Kα inhibitor designed for the use in human cancer therapy [9]. It was tested in several clinical trials
alone or in combination with other chemotherapeutics against solid tumors [10–12]. Here, we tested
proliferation, induction of apoptosis, and signaling pathway activation in two-dimensional (2D) and
three-dimensional (3D) cultures of PTEN-haploinsufficient primary lipoma cells treated with alpelisib.
We aimed to determine whether alpelisib has growth-restrictive effects and would induce cell death in
lipoma cell cultures from pediatric patients with PHTS.
2. Results
2.1. Effect of Alpelisib on Proliferation of Lipoma Cells
2.1.1. Alpelisib Reduced Cell Viability in a Dose- and Time-Dependent Manner
We treated five different primary lipoma cell cultures with alpelisib concentrations ranging
from 1 to 50 µM and measured cell viability (the number of metabolically active cells) using the
WST-1 assay after 72 h for alpelisib alone (Figure 1a) or in combination with 10 nM rapamycin
(Figure 1b). Additionally, we tested cell viability at different time points (24–144 h) in LipPD1 cells for
alpelisib alone (Figure 1c) and in combination with rapamycin (Figure 1d).
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Figure 1. WST-1 cell viability assay after alpelisib or alpelisib+rapamycin treatment of lipoma cell 
cultures from three PTEN Hamartoma Tumor Syndrome (PHTS) patients (LipPD1-3) and two 
PIK3CA-related overgrowth spectrum (PROS) patients (Lip3-4): (a) 72 h alpelisib treatment reduced 
cell viability at concentrations ≥10 µM in all tested cell cultures; (b) a 72 h combined treatment with 
alpelisib and rapamycin further decreased cell viability; (c) 24–144 h treatment of 
PTEN-haploinsufficient LipPD1 cells at 1 to 100 µM alpelisib reduced cell viability; (d) 24–144 h 
combined treatment with alpelisib and/or rapamycin further decreased viability. Fold over solvent 
control (black line), n = 3, * p ≤ 0.05.  
We noted a concentration-dependent decrease in cell viability for all cell cultures (p < 0.0001). At 
10 µM alpelisib, cell viability was significantly decreased in all cell cultures. A combination of 10 µM 
alpelisib and 10 nM rapamycin further decreased cell viability compared to single treatment (p < 
0.001). IC50 values for 72 h WST-1 assays were calculated to be 9.09 µM (LipPD1), 6.31 µM (LipPD2), 
18.33 µM (LipPD3), 6.7 µM (Lip3), and 15.74 µM (Lip4). A summary of all IC50 values is given in 
supplementary Table S1. We found similar effects for PHTS (LipPD1-3) and PROS patients’ lipoma 
cells (Lip3 and Lip4). During six days of treatment, cell viability decreased in a concentration- (p < 
0.0001) and time-dependent manner (p < 0.0001). We observed a further decrease in cell viability for 
a combined treatment of alpelisib and rapamycin. To examine whether combining alpelisib and 
rapamycin has synergistic or additive anti-lipoma activity, LipPD1, LipPD2, and LipPD3 cells were 
treated with alpelisib and rapamycin across a range of concentrations. Analysis of the combined 
effect by the Chou and Talalay method [13] showed a significant decrease in viability after 
co-treatment compared to either agent alone, with a combination index of <1.0 in all tested cells. 
Overall, these data confirmed the synergistic anti-lipoma activity of this drug combination 
(supplementary Figure S1).  
2.1.2. Alpelisib Inhibited Lipoma Cell Proliferation 
To analyze whether the effects seen in the WST-1 assays are caused by an inhibition of 
proliferation, we counted Hoechst-stained nuclei of lipoma cells after alpelisib, rapamycin, or 
combined treatment (Figure 2a–d) and performed immunofluorescence staining of the proliferation 
marker Ki-67 in LipPD1 cells after 48 h alpelisib treatment (Figure 2e–f). 
Figure 1. WST-1 cell viability assay after alpelisib or alpelisib+rapamycin treatment of lipoma cell cultures
from three PTEN Hamartoma Tumor Syndrome (PHTS) patients (LipPD1-3) and two PIK3CA-related
overgrowth spectrum (PROS) patients (Lip3-4): (a) 72 h alpelisib treatment reduced cell viability at
concentrations≥10µM in all tested cell cultures; (b) a 72 h combined treatment with alpelisib and rapamycin
further decreased cell viability; (c) 24–144 h treatment of PTEN-haploinsufficient LipPD1 cells at 1 to 100 µM
alpelisib reduced cell viability; (d) 24–144 h combined treatment with alpelisib and/or rapamycin further
decreased viability. Fold over solvent control (black line), n = 3, * p ≤ 0.05.
We noted a concentration-dependent decrease in cell viability for all cell cultures (p < 0.0001).
At 10 alpelisib, cell viability was sig ificantly decreased in all cell cultures. A combination of
10 µM alpelisib and 10 nM rapamycin further decr ased cell viability compared o single treatment
(p < .001). IC50 values for 72 h WST-1 assays were calculated to be 9.09 µM (LipPD1), 6.31 µM
(LipPD2), 18.33 µM (LipPD3), 6.7 µM (Lip3), and 15.74 µM (Lip4). A summary of all IC50 values is
given in supplementary Table S1. We found similar effects for PHTS (LipPD1-3) and PROS patients’
lipoma cells (Lip3 and Lip4). During six days of treatment, cell viability decreased in a concentration-
(p < 0.0001) and time-dependent manner (p < 0.0001). We observed a further decrease in cell viability
for a combined treatment of alpelisib and rapamycin. To examine whether combining alpelisib and
rapamycin has synergistic or additive anti-lipoma activity, LipPD1, LipPD2, and LipPD3 cells were
treated with alpelisib and rapamycin across a range of concentrations. Analysis of the combined effect
by the Chou and Talalay method [13] sh wed a significant decrease in viability after co-treatment
compared to either agent alone, wit a combination index of <1.0 in all tes ed cells. Overall, these data
confirmed the syner istic anti-lipoma activity of this drug combination (supplementary Figure S1).
2.1. . Alpelisib Inhibited Lipo roliferation
To analyze whether the effects seen in the WST-1 assays are caused by an inhibition of proliferation,
we counted Hoechst-stained nuclei of lipoma cells after alpelisib, rapamycin, or combined treatment
(Figure 2a–d) and performed immunofluorescence staining of the proliferation marker Ki-67 in
LipPD1 cells after 48 h alpelisib treatment (Figure 2e–f).
Alpelisib attenuated growth of all three lipoma cell cultures alone and in combination with
rapamycin. For LipPD1 cells treated with 100 µM alpelisib, cell count was stable for six days in
culture. The same observation was made for a combination of 10 µM alpelisib and 10 nM rapamycin.
IC50 values for 72 h Hoechst assays were calculated to be 15.91 µM (LipPD1), 10.06 µM (LipPD2),
and 15.79 µM (LipPD3) (supplementary Table S1). The fraction of Ki-67 positive cells was reduced
after alpelisib treatment for 1 µM to 0.75 ± 0.07 fold (p = 0,074), for 10 µM to 0.55 ± 0.06 fold (p = 0.018),
and for 100 µM to 0.22 ± 0.1 fold (p = 0.017) in a concentration-dependent manner (p = 0.0098).
Ki-67 immunofluorescence staining in LipPD2 and LipPD3 cells after 72 h also showed a reduced
fraction of proliferation marker positive cells (supplementary Figure S2a).
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Figure 2. Hoechst proliferation assay and Ki-67 proliferation marker immunofluorescence staining 
after alpelisib/alpelisib+rapamycin treatment in PTEN-haploinsufficient lipoma cell cultures: (a) 72 h 
alpelisib treatment attenuated proliferation in a concentration-dependent manner in three different 
lipoma cell cultures; (b) a combined treatment with alpelisib and rapamycin further decreased cell 
count. Fold over solvent control, n = 3, * p ≤ 0.05. (c) Cell counts in LipPD1 cells during six days of 100 
µM alpelisib (alp) treatment did not increase, while cells in solvent control proliferated; (d) a 
combination of rapamycin (rap) and alpelisib further decreased proliferation compared to treatment 
with alpelisib or rapamycin alone. n ≥ 3, * p ≤ 0.05 compared to solvent control. (e) Ki-67 proliferation 
marker immunofluorescence staining of LipPD1 cells after 48 h of alpelisib treatment: Merged image 
of nuclei (blue) and Ki-67 (green) for untreated and 10 µM alpelisib treated cells; (f) fraction of Ki-67 
positive cells is decreased after alpelisib treatment, fold over solvent control (black line), n = 3, * p ≤ 
0.05. 
Figure 2. Hoechst proliferation assay and Ki-67 proliferation arker immunofluorescence staining
after alpelisib/alpelisib+rapamycin treatment in PTEN-haploinsufficient lipoma cell cultures: (a) 72 h
alpelisib treatment attenuated proliferation in a concentration-dependent manner in three different
lipoma cell cultures; (b) a combined treatment with alpelisib and rapamycin further decreased cell count.
Fold over solvent control, n = 3, * p ≤ 0.05. (c) Cell counts in LipPD1 cells during six days of 100 µM
alpelisib (alp) treatment did not increase, while cells in solvent control proliferated; (d) a combination
of rapamycin (rap) and alpelisib further decreased proliferation compared to treatment with alpelisib
or rapamycin alone. n ≥ 3, * p ≤ 0.05 compared to solvent control. (e) Ki-67 proliferation marker
immunofluorescence staining of LipPD1 cells after 48 h of alpelisib treatment: Merged image of nuclei
(blue) and Ki-67 (green) for untreated and 10 µM alpelisib treated cells; (f) fraction of Ki-67 positive
cells is decreased after alpelisib treatment, fold over solvent control (black line), n = 3, * p ≤ 0.05.
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2.2. Cytotoxicity of Alpelisib in Lipoma Cells
We measured apoptosis induction in lipoma cells after 72 h alpelisib treatment by annexin V/PI
staining via flow cytometry (Figure 3a), and cell death after 24 h and 72 h via LDH-cytotoxicity assay
(Figure 3b).
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Figure 3. Apoptosis/cell death of PTEN Hamartoma Tumor Syndrome (PHTS, LipPD1-3) and
PIK3CA-related overgrowth spectrum (PROS, Lip3-4) patients’ lipoma cells after 50 µM alpelisib
and/or 10 nM rap mycin treatment. (a) Apopt tic/dea cells determined via annexin V/PI staining did
not increase ompared to solvent control in LipPD1 and Lip3 cells, whil 50 µM perifosine (PC, positive
control) l d to cel d ath. A minor rise in the fraction of apoptotic/dead cells was observed for Lip4 and
for a combination with 10 nM rapamycin i LipPD1 cells. (b) LDH cytotoxicity assay in LipPD1-3 cells
showed no increa e in cell death after 24 h or 72 h 50 µM alpelisib and/or 10 nM rapamycin treatment.
PC: Cell lysis positive control, n = 3, * ≤ 0.05.
We did not observe cell eat after 72 50 µM alpelisib treatment in LipPD1 and Lip3 cells.
The fraction of viable cells was slightly reduced in Lip4 cells after 50 µM alpelisib treatment compared
to solvent control. The fraction of ea a a o totic cells as highly elevated in the positive control
(50 µM perifosine). For LipPD1 cells, we did not observe apoptosis after 72 h 10 nM rapamycin
treatment alone, while the total fraction of apoptotic and dead cells was slightly increased (by
9.6 ± 2.3%, p = 0.0471) after a combined treatment with alpelisib and rapamycin. To confirm our
findings, we performed LDH cytotoxicity assays for LipPD1, LipPD2, and LipPD3 cells after 24 h and
72 h of 50 µM alpelisib treatment (Figure 3b). We did not observe any additional LDH release in 50 µM
alpelisib treated lipoma cells, implying no induction of cell death. We neither observed cytotoxicity for
10 nM rapamycin nor a combination of 50 µM alpelisib with 10 nM rapamycin.
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2.3. Effect of Alpelisib on PI3K Signaling
To determine whether alpelisib affects downstream PI3K signaling, we performed Western blot
analyses, qPCRs, and immunofluorescence staining of alpelisib-treated LipPD1 cells to detect activated
signaling components.
2.3.1. Alpelisib Reduced PI3K/AKT/mTOR Pathway Activation in Lipoma Cells
To determine basal pathway activation, cells were treated with alpelisib for 24 h and AKT, mTOR,
and ribosomal protein S6 phosphorylation was determined via Western blot analysis (Figure 4a–c).
pS6-immunofluorescence staining of LipPD1 cells was performed after 48 h alpelisib treatment
(Figure 4d–e).
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staining after 48 h treatment with alpelisib (alp) and/or rapamycin (rap), representative blots and 
densitometric analysis: (a) Phosphorylated AKT (phospho-Thr 308 (pAKT) normalized to total AKT) 
was reduced after alpelisib but not rapamycin treatment; (b) phosphorylation of mTOR 
(phospho-Ser 2448 (pmTOR) normalized to total mTOR); (c) phosphorylation of ribosomal protein S6 
(phospho-Ser 235/236 (pS6) normalized to total S6 protein) was reduced after alpelisib and 
rapamycin treatment. One representative blot out of three for each protein (phosphorylated and 
total) and densitometric analysis of three independent experiments is shown, fold over solvent 
Figure 4. West rn blot analysis of LipPD1 cells aft r 24 h treatment and pS6 immunofluorescence staining
after 48 h treatment with lpelisib (alp) and/or rapamycin (rap), representative blots and densitometric
analysis: (a) Phosphorylated AKT (phospho-Thr 308 (pAKT) normalized to total AKT) was reduced
after alpelisib but not apamycin treatme t; (b) hosphorylation of mTOR ( s ho-Ser 2448 (pmTOR)
normalized to total mTOR); (c) phosphorylation of ribosomal r tein S6 (ph spho-Ser 235/236 (pS6)
normalized to total S6 protein) was reduced after alpelisib and rapamycin treatment. One epresentative
blot out of three for each prot in (phosphorylated and otal) and densit metric analysis of three
independent experiments is shown, f ld over solvent control, * p ≤ 0.05. (d) Merged image of nuclei
(blue) and pS6 (green) immunofluorescence staining for untreated and 10 µM alpelisib-treated cells;
(e) fraction of pS6 positive cells decreased after alpelisib treatment, fold over solvent control (black
line), n = 3, * p ≤ 0.05.
AKT activation was reduced in 50 µM alpelisib-treated cells (p = 0.019), while rapamycin enhanced
AKT phosphorylation (p = 0.192). This effect of rapamycin was repressed when combined with alpelisib
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(p = 0.279). Activation of mTOR was reduced in 10 µM (p = 0.099) and 50 µM (p = 0.066) alpelisib-treated
cells, as well as in 10 nM rapamycin-treated cells (p = 0.18). Phosphorylation of S6 was significantly
reduced for all tested alpelisib and rapamycin concentrations. Western blots for LipPD2 (supplementary
Figure S3) and LipPD3 (supplementary Figure S4) cells showed similar results. All blots, GAPDH
loading control blots and densitometric analyses are provided in supplementary Figures S5–S7 and
supplementary Table S2–S3. In immunofluorescence staining experiments, the fraction of pS6 positive
cells was reduced after alpelisib treatment for 10 µM to 0.57 ± 0.02 fold (p = 0.0074) and for 100 µM to
0.01 ± 0.006 fold (p = 0.0169). pS6 immunofluorescence staining in LipPD2 and LipPD3 cells after 72 h
showed similar results (supplementary Figure S2b).
2.3.2. Alpelisib Reduced PCNA, GLUT1, and PGK mRNA Expression
To determine the influence of alpelisib on gene expression, we performed reverse transcription
quantitative PCR (RT-qPCR) analysis for the proliferation marker PCNA, the glucose transporter
GLUT1, and the glycolysis enzyme PGK (Figure 5). All three genes are known to be regulated by PI3K
signaling [14–16].
Cancers 2019, 11, x 7 of 17 
 
control, * p ≤ 0.05. (d) Merged image of nuclei (blue) and pS6 (green) immunofluorescence staining 
for untreated and 10 µM alpelisib-treated cells; (e) fraction of pS6 positive cells decreased after 
alpelisib treatment, fold over solvent control (black line), n = 3, * p ≤ 0.05. 
AKT activation was reduced in 50 µM alpelisib-treated cells (p = 0.019), while rapamycin 
enhanced AKT phosphorylation (p = 0.192). This effect of rapamycin was repressed when combined 
with alpelisib (p = 0.279). Activation of mTOR was reduced in 10 µM (p = 0.099) and 50 µM (p = 0.066) 
alpelisib-treated cells, as well as in 10 nM rapamycin-treated cells (p = 0.18). Phosphorylation of S6 
was significantly reduced for all tested alpelisib and rapamycin concentrations. Western blots for 
LipPD2 (supplementary Figure S3) and LipPD3 (supplementary Figure S4) cells showed similar 
results. All blots, GAPDH loading control blots and densitometric analyses are provided in 
supplementary Figures S5–S7 and supplementary Table S2–S3. In immunofluorescence staining 
experiments, the fraction of pS6 positive cells was reduced after alpelisib treatment for 10 µM to 0.57 
± 0. 2 fold (p = 0.0074) and for 100 µM to 0.01 ± 0.006 fold (p = 0.0169). pS6 immunofluorescenc  
staining in LipPD2 and LipPD3 cells after 72 h showed similar results (supplementary Figure S2b). 
3.2. Alpelisib Reduced PCNA, , and PGK mRNA Expression  
To determine the influence of alpelisib on gene expression, we performed reverse transcription 
quantitative PCR (RT-qPCR) analysis for the proliferation marker PCNA, the glucose transporter 
GLUT1, and the glycolysis enzyme PGK (Figure 5). All three genes are known to be regulated by 
PI3K signaling [14–16]. 
 (a)  (b)  (c) 
Figure 5. RT-qPCR of cell cycle and glucose metabolism genes from LipPD1 cells after 24 h treatment 
with 10 µM alpelisib: mRNA expression of (a) PCNA, (b) GLUT1, and (c) PGK was downregulated in 
10 µM alpelisib-treated cells. Fold over control, values were normalized to the housekeeper gene 
TBP, n = 6, * p ≤ 0.05, ** p ≤ 0.01. 
PCNA mRNA was downregulated after 24 h alpelisib treatment (to 0.67 ± 0.08 fold). Similarly, 
we observed a downregulation of GLUT1 mRNA (to 0.60 ± 0.11 fold) and PGK mRNA (to 0.67 ± 0.06 
fold). 
2.4. Effect of Alpelisib on Adipocyte Differentiation in 2D and 3D Models 
To test whether alpelisib would attenuate adipogenesis, we differentiated LipPD1 cells in 2D 
culture and 3D spheroid models to assess lipid accumulation (Figure 6a–b), differentiation markers 
(2D) (Figure 6c–e), and spheroid size (3D) (Figure 6f–g). 
Figure 5. RT-qPCR of cell cycle and glucose metabolism genes from LipPD1 cells after 24 h treatment
with 10 µM alpelisib: mRNA expression of (a) PCNA, (b) GLUT1, and (c) PGK was downregulated in
10 µM alpelisib-treated cells. Fold over control, values were normalized to the housekeeper gene TBP,
n = 6, * p ≤ 0.05, ** p ≤ 0.01.
PCNA mRNA was downregulated after 24 h alpelisib treatment (to 0.67 ± 0.08 fold).
Similarly, we observed a downregulation of GLUT1 mRNA (to 0.60 ± 0.11 fold) and PGK mRNA (to
0.67 ± 0.06 fold).
2.4. Effect of Alpelisib on Adipocyte Differentiation in 2D and 3D Models
To test whether alpelisib would attenuate adipogenesis, we differentiated LipPD1 cells in 2D
culture and 3D spheroid models to assess lipid accumulation (Figure 6a–b), differentiation markers
(2D) (Figure 6c–e), and spheroid size (3D) (Figure 6f–g).
We observed reduced lipid accumulation after alpelisib treatment of LipPD1 cells in adipocyte
differentiation medium for 10 days. The fraction of adipocytes was reduced from 54.8 ± 7% to 29.9 ± 7%.
Further, we investigated the mRNA expression of differentiation markers with or without 10 µM
alpelisib in adipogenic medium and detected peroxisome proliferator-activated receptor γ (PPARγ) mRNA
downregulated after 10 days in differentiation medium with 10 µM alpelisib to 0.55 ± 0.06 fold.
Adiponectin mRNA was downregulated to 0.54 ± 0.04 fold and adipocyte protein 2 (aP2) mRNA to
0.54± 0.03 fold. Fatty acid synthase (FASN) mRNA was downregulated as well to 0.58± 0.09 fold, p = 0.064
(supplementary Figure S8). To confirm our findings, we evaluated the effect of alpelisib treatment on
adipocyte differentiation in a 3D spheroid model [17]. While the size of control 3D-spheroids increased
during in vitro differentiation (to 1.25 ± 0.06 fold after 10 days), the size of 10 µM alpelisib-treated
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spheroids was reduced after 4 days (to 0.78 ± 0.05 fold) and, afterwards, stable throughout the duration
of the experiment (to 0.79 ± 0.05 fold after 10 days). The differences between controls and alpelisib
treated cells were significant from day 4 on (p = 0.0063 at day 4).
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Figure 6. Alpelisib treatment of LipPD1 cells during adipocyte differentiation: (a) Oil Red O lipid 
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differentiation medium was decreased with 10 µM alpelisib (alp) compared to solvent control, n = 3, * 
p = 0.016. RT-qPCR of adipogenesis-related genes in LipPD1 cells after 10 days of differentiation with 
or without 10 µM alpelisib: mRNA expression of (c) PPARγ, (d) Adiponectin, and (e) aP2 was 
downregulated in 10 µM alpelisib-treated cells. Fold over control, values were normalized to the 
housekeeper gene β-actin, n = 3, * p ≤ 0.05, ** p ≤ 0.01. (f) 10 µM alpelisib treatment of 3D LipPD1 cell 
cultures during adipocyte differentiation; (e) size of 3D lipoma spheroids during 10 days in 
differentiation medium decreased with 10 µM alpelisib (alp) compared to day 1, values for day 1 
were calculated by normalizing to the mean of day 1; for following days, each spheroid size was 
divided by the size of the same spheroid at day 1, n = 4, * p ≤ 0.05. 
Figure 6. Alpelisib treatment of LipPD1 cells during adipocyte differentiation: (a) Oil Red O lipid (red)
and Hoechst (blue) staining after 10 days in differentiation medium showed reduced lipid accumulation
after 10 µM alpelisib treatment; (b) the percentage of adipocytes after 10 days in differentiation medium
was decreased with 10 µM alpelisib (alp) compared to solvent control, n = 3, * p = 0.016. RT-qPCR
of adipogenesis-related genes in LipPD1 cells after 10 days of differentiation with or without 10 µM
alpelisib: mRNA expression of (c) PPARγ, (d) Adiponectin, and (e) aP2 was downregulated in 10 µM
alpelisib-treated cells. Fold over control, values were normalized to the housekeeper gene β-actin,
n = 3, * p ≤ 0.05, ** p ≤ 0.01. (f) 10 µM alpelisib treatment of 3D LipPD1 cell cultures during adipocyte
differentiation; (e) size of 3D lipoma spheroids during 10 days in differentiation medium decreased
with 10 µM alpelisib (alp) compared to day 1, values for day 1 were calculated by normalizing to the
mean of day 1; for following days, each spheroid size was divided by the size of the same spheroid at
day 1, n = 4, * p ≤ 0.05.
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2.5. Effect of Alpelisib on Senescence of Lipoma Cells
To check whether the lipoma cells maintained their mesenchymal stem cell phenotype or
underwent senescence during alpelisib treatment, we performed a β-galactosidase senescence staining
(Figure 7a–b) and measured gene expression of stem cell and senescence markers (Figure 7c–e).
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Figure 7. β-galactosidase senescence staining of LipPD1 cells after 72 h alpelisib treatment: (a) 
β-galactosidase staining showed a higher number of senescent (blue) cells after 10 µM alpelisib
treatment; (b) the fraction of senescent cells increased with 10 µM alpelisib compared to solvent 
control, n = 3, * p = 0.027. RT-qPCR of senescence and stem cell marker genes from LipPD1 cells after 
10 days of differentiation with or without 10 µM alpelisib: mRNA expression of (c) p16 was 
upregulated, (d) CD44 was upregulated (p = 0.053), and (e) CD90 was downregulated in 10 µM 
Figure 7. β-galacto idase enescence staining of LipPD1 cells after 72 h alpelisib treatment:
(a) β-galactosid se staining showed a higher number of senescent (blu ) cells after 10 µM alpelisib
treatment; (b) the fracti senescent cells increased with 10 µM alpelisib compared to solvent control,
= 3 * p = 0.027. RT-qPCR of senesc ce and stem cell marker genes from LipPD1 cells after 10 days
of differentiation with or it out 10 µM alpelisib: mRNA expression of (c) p16 was upregulated,
(d) CD44 was upregulated ( = 0.053), and (e) CD90 was downregul te in 10 µM alpelisib-treated
cells. Fold over control, values were normalized to the housekeeper gene β-actin, n = 3, * p ≤ 0.05.
The fraction of senescent cells after 72 h alpelisib treatment was elevated 2.71± 0.47 fold, indicating
cell cycle arrest. Similar observations were made for LipPD2 (2.43 ± 0.7 fold, p = 0.236) and LipPD3 cells
(4.96 ± 1.98 fold, p = 0.065) (supplementary Figure S9). Since we observed an inhibition of adipogenesis
through alpelisib, we investigated whether these undifferentiated cells would retain their mesenchymal
stem cell state or undergo senescence by analyzing the mRNA expression of senescence marker
CDKN2A (p16) and stem cell markers CD44 and Thy-1 (CD90) with or without 10 µM alpelisib in
adipogenic medium. p16 mRNA was upregulated after 10 days in differentiation medium with 10 µM
alpelisib (to 5.4 ± 2.05 fold). CD44 mRNA was upregulated to 1.96 ± 0.32 fold. In contrast, CD90
mRNA was reduced to 0.71 ± 0.05 fold. Similar trends in the regulation of adiponectin, p16, CD44, and
CD90 were observed in LipPD2 and LipPD3 cells (supplementary Figure S10).
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3. Discussion
Lipomatosis associated with germline mutations in PTEN can be a severe complication in pediatric
patients. So far, the only treatment option is surgical resection, which is not feasible in every patient
and has to be repeated because of lipoma recurrence. In this research work, we tested effects of the
novel PI3K inhibitor alpelisib on PTEN-haploinsufficient lipoma cells (stromal-vascular fraction) from
pediatric patients. Proliferation of these preadipocyte-like cells is enhanced, potentially due to a
constitutive overactivation of the PI3K-pathway [18]. The PI3K/AKT/mTOR axis acts as a major growth
factor signaling pathway regulating proliferation and survival [19]. In adipose tissue, PI3K signaling
is essential for adipocyte differentiation [20]. We asked whether alpelisib influences these cellular
responses and, by doing so, can inhibit growth of lipoma cells.
When we treated lipoma cells with alpelisib, we observed a concentration-dependent decrease
in cell viability. This decrease was in line with a reduced cell number after alpelisib treatment.
The fraction of proliferation marker Ki-67 positive cells was decreased in a concentration-dependent
manner and the proliferation marker PCNA was downregulated on the mRNA level. While these
findings indicate that alpelisib negatively influences cell proliferation of PTEN-haploinsufficient lipoma
cells, apoptosis could not be induced during 72 h alpelisib treatment. Indeed, we did not detect
any alpelisib-induced cytotoxicity in any of the cell lines tested. The number of dead/apoptotic cells
was also only slightly elevated when we combined the mTOR inhibitor rapamycin with alpelisib.
Nevertheless, this combination was more effective than treatment with the same concentrations of either
drug alone in terms of inhibition of proliferation. Supporting this finding, we detected a synergistic
effect of rapamycin and alpelisib treatment on cell viability. In line with the findings of Keam et al.,
in head and neck cancer cell lines, we detected a reduction of proliferation using alpelisib at similar
concentrations [21].
In the majority of cancers with mutated PI3K, the PI3Kα isoform is activated [22]. Alpelisib is
a selective PI3Kα inhibitor [9]. As hypothesized, alpelisib inhibited phosphorylation and, therefore,
activation of AKT in the lipoma cells. This also affected the downstream PI3K-pathway molecule
ribosomal protein S6, which is phosphorylated by the ribosomal protein S6 kinase beta 1 (S6K1). S6K1 is
known to be a key molecule in transcriptional regulation of cell cycle and cell size [23]. Alpelisib inhibited
S6 phosphorylation to the same extent as direct mTOR inhibition through rapamycin. We found that
after 48 h treatment with 100 µM alpelisib, only approximately 1% of cells showed S6 phosphorylation.
When treating lipoma cells with rapamycin, we observed an increased phosphorylation of AKT,
confirming earlier findings in lipoma cells [4]. This AKT activation induced by inhibition of the
negative feedback regulation by mTORC1 [7] could be reversed when combining rapamycin with
10 µM alpelisib. This indicates that resistance mechanisms occurring during rapamycin treatment of
PHTS patients might be overcome when co-treating with alpelisib. Moreover, an inhibition of further
upstream molecules of the PI3K pathway through alpelisib may overcome the limitations of targeting
mTOR. PTEN directly antagonizes PI3K, and in patients with germline PTEN mutations, this leads to
an activation of the whole pathway. PI3K inhibitors limit this pathway activation on the same level as
PTEN, which might provide advantages over an inhibition further downstream.
Many cancer cells are known to rely on aerobic glycolysis as their primary source of energy
generation. The PI3K pathway plays a major role in regulating this metabolic process [24]. To further
dissect molecular causes for the observed growth arrest after alpelisib treatment, we quantified gene
expression of the glucose transporter GLUT1 and the glycolysis enzyme PGK. Both were significantly
reduced, indicating changes in glucose metabolism on the transcriptional level during alpelisib
treatment, along with a reduction of proliferating cell nuclear antigen (PCNA) expression, a marker for
proliferating cells. In patients, this might be advantageous to mainly target cells with a transformed
metabolic profile, and therefore selectively inhibit malignancies.
To test alpelisib in a physiological model of lipoma adipocyte differentiation, we used 3D cultures
of lipoma cells. Size of lipoma cell spheroids in 3D culture increased during 10 days in differentiation
medium, as shown before [17], which is probably due to a cell volume increase because of lipid
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accumulation. This effect was not observed when treating lipoma spheroids with 10µM alpelisib, which,
in contrast, led to a reduced spheroid size. This could result both from an inhibition of differentiation
and from a reduction of cell size through downregulation of S6 phosphorylation [25]. In PHTS patients,
a reduction in lipoma size without surgery could counteract disease progression, and therefore prevent
life-threatening complications. mTOR is known to regulate adipocyte differentiation through PPARγ,
the master transcriptional regulator of adipogenesis [26]. Similar to rapamycin [27], we found that
alpelisib reduced adipocyte differentiation in 2D lipoma cells culture as well. The differentiation
markers PPARγ, adiponectin, aP2, and FASN were downregulated.
We finally tested whether the attenuated adipocyte differentiation observed in alpelisib-treated
lipoma cells was caused by preservation of stem cell characteristics. When checking gene expression
of CD44 and CD90, markers present on adipose-derived mesenchymal stem cells, we found gene
expression differences in differentiated lipoma cells that were alpelisib-treated compared to controls.
We found that the stem cell marker CD90 was downregulated. CD90 downregulation is associated with
senescence in mesenchymal stem cells [28]. In contrast, CD44 was upregulated. Although considered
a mesenchymal stem cell marker [29], CD44 was also found to be a senescence-induced cell adhesion
gene [30]. Supporting these data, we detected upregulation of CDKN2A (p16) by alpelisib, both
in differentiated and undifferentiated lipoma cells. Moreover, alpelisib enhanced β-galactosidase
staining of lipoma cells. These findings indicate that alpelisib induced senescence both in PTEN
haploinsufficient preadipocytes and differentiated adipocytes. In a mouse model for PROS syndrome,
no induction of senescence or apoptosis was detected [8].
Alpelisib was successfully used to treat overgrowth of different tissues associated with activating
PI3K mutations in PROS patients [8]. Since activating PI3K mutations and deactivating PTEN mutations
both activate the PI3K-pathway, we hypothesize beneficial effects of alpelisib for PHTS patients as well.
In our cell culture experiments, we indeed observed similar effects on cell viability in PROS and PHTS
patients’ lipoma cells. We found growth-inhibitory effects with PI3K-pathway inhibition and reduction
in size of in vitro lipoma 3D models. The main adverse event found in clinical trials with alpelisib was
hyperglycemia [10–12]. Alpelisib was tested in a set of pediatric patients with PROS where it was well
tolerated, and side effects were reported to be mild and manageable [8]. We therefore consider alpelisib
as a potential future alternative to rapamycin treatment or as an option for combination therapy with
rapamycin for patients with PHTS-associated lipoma. As a next step, we propose testing of alpelisib
in vivo. We will test effects of alpelisib on PTEN knockout and wildtype tissues in a conditional
PTEN-knock-out mouse model and investigate the reversibility of these effects.
4. Materials and Methods
4.1. Cell Culture and Adipocyte Differentiation
We used cells of the stromal vascular fraction isolated from lipomas of three different pediatric
PHTS and two PROS patients (Leipzig University ethical approval: no. 425-12-171220). Mutations were
detected by Sanger sequencing [18], while the PTEN deletion seen in LipPD1 was analyzed by
multiplex ligation-dependent probe amplification (MLPA) and array-based comparative genomic
hybridization (Array-CGH) [4]. A reduction in PTEN mRNA and/or protein, as well as increased AKT
phosphorylation, compared to PTEN wildtype controls was found [18]. Isolation and culture methods
were described previously [4,18]. Table 1 contains a list of the lipoma cells used.
Table 1. Lipoma cells from pediatric PHTS and PROS patients [18].
Name Sex Age at Resection Mutation
LipPD1 male 3 Heterozygous deletion of PTEN exons 2-9 of 9
LipPD2 male 3 PTEN heterozygous point mutation (c.404T>A, p.I135K)
LipPD3 female 4 PTEN heterozygous point mutation (exon 1, c.76A>C, p.T26P)
Lip3 female 14 Mosaic PI3KCA mutation (10%) (exon 10, c.1624G>A, p.(Glu542Lys)
Lip4 male 13 Mosaic PI3KCA mutation (30-40 %) (exon 8, c.1340_1366del, p.(Pro447_Leu455del)
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For differentiation, we plated 13,000 lipoma cells/cm2 in culture medium and changed medium to
differentiation medium (DMEM/F12 containing 2 µmol/L rosiglitazone, 25 nmol/L dexamethasone,
0.5 mmol/L methylisobuthylxantine, 0.1 µmol/L cortisol, 0.01 mg/mL apotransferrin, 0.2 nmol/L
triiodotyronin, and 20 nmol/L human insulin [31]) after 24 h. Cells were incubated with 10 µM alpelisib
(Selleckchem, Munich, Germany) or solvent control (DMSO) in differentiation medium for 10 days.
The medium was replaced every 72 h. For lipid staining, cells were fixed in Roti-Histofix 4% (Carl
Roth GmbH, Karlsruhe, Germany), washed with DPBS, and stained with Oil Red O solution (0.03% in
60% isopropanol, Sigma, St. Louis, MO, USA) for 15 min at 37 ◦C [32]. For transcriptional comparison
to undifferentiated cells, these were kept in serum-free culture medium for 4 days.
A modified method according to Klingelhutz et al. was used for scaffold-free 3D cultures of
lipoma cells [17]. To form spheroids, 10,000 cells per well were seeded into low attachment 96-well
microplates (PS, U-bottom, clear, cellstar®, cell-repellent surface, Greiner Bio-One, Kremsmünster,
Austria) in 100 µl differentiation medium and incubated for 24 h. After 24 h, spheroids were incubated
with 10 µM alpelisib or solvent control in differentiation medium for 10 days. Half of the medium was
replaced every 72 h. Microscope images were taken daily using the EVOS FL Auto 2 Cell Imaging
System (Invitrogen; Thermo Fisher Scientifc, Inc., Waltham, MA, USA). Image analysis to determine
the spheroid size was performed using ImageJ [33].
4.2. Cell Viability/Proliferation
For proliferation assays, cells were seeded at a density of 3000 cells/well (24 h) or 1500 cells/well
(48–144 h) on 96-well plates and treated with different concentrations of alpelisib and/or rapamycin
(both Selleckchem, Munich, Germany). Medium was replaced every 72 h. Cell viability measures
were performed using the Cell Proliferation Reagent WST-1 (Roche Diagnostics GmbH, Mannheim,
Germany) according to the manufacturer’s protocol. After WST-1 assay, cells were fixed and nuclei
were stained with Hoechst 33342 (Sigma, Munich, Germany) for 5 min at a concentration of 10 µg/ml
in DPBS. Hoechst fluorescence was detected at 455 nm.
4.3. Apotosis Assay
For apoptosis detection, cells were seeded at a density of 1750 cells/cm2 and treated with
alpelisib/alpelisib+rapamycin for 72 h. Then, 50 µM perifosine (Selleckchem, Munich, Germany) was
used as a positive control. The FITC-Annexin V Apoptosis Detection Kit I (BD Pharmingen, Franklin
Lakes, NJ, USA) was used for annexinV–fluorescein isothiocyanate and propidium iodide staining of
the trypsinized cells. Apoptosis was detected by flow cytometry.
4.4. LDH Cytotoxcicity Assay
For LDH cytotoxicity assays, cells were seeded at a density of 3000 cells/well on 96-well plates in
culture medium. Cells were treated for 72 h with 50 µM alpelisib, 10 nM rapamycin, or a combination of
both. LDH release was detected using the CyQUANT™ LDH Cytotoxicity Assay (Invitrogen; Thermo
Fisher Scientifc, Inc., Waltham, MA, USA) according to the manufacturer’s protocol.
4.5. Western Blot Analysis
For Western blot analysis, lipoma cells were seeded at a density of 10,000 cells/cm2 in culture
medium. Cells were incubated with different alpelisib and/or rapamycin concentrations for 24 h.
Proteins were extracted and immunoblotting was performed as described elsewhere [4]. We used 10 µg
protein per lane and incubated with primary antibodies (Cell Signaling Technology, Inc., Danvers, MA,
USA) and secondary antibodies (Dako; Agilent Technologies, Inc., Santa Clara, CA, USA), according to
Table 2. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) (Merck KGaA, Darmstadt, Germany)
was used as loading control.
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Table 2. Antibodies used for Western blot (Wb) and immunofluorescence staining (IF).
Primary Antibody Dilution Supplier Cat. no
mTOR (7C10) Rabbit mAb 1:1000 TBS-T 5%BSA (Wb) CST #2983
Phospho-mTOR (Ser2448) Rabbit mAb (D9C2) 1:1000 TBS-T 5%BSA (Wb) CST #5536
AKT antibody Rabbit polyclonal Ab 1:1000 TBS-T 5%BSA (Wb) CST #9272
Phospho-AKT (Thr308) (224F9) Rabbit mAb 1:500 TBS-T 5%BSA (Wb) CST #4056
S6 ribosomal protein (5G10) Rabbit mAb 1:1000 TBS-T 5%BSA (Wb) CST #2217
Phospho-S6 Ribosomal protein (Ser235/236) (D57.2.2E)
XP® Rabbit mAb
1:1000 TBS-T 5%BSA (Wb)
1:500 IF-buffer (IF) CST #4858
GAPDH (6C5) Mouse mAb 1:50,000 TBS-T 5% milk (Wb) Merck MAB374
KI-67 (MIB-1) Mouse mAb 1:200 IF-buffer (IF) Dako P0447
Secondary antibody Dilution Supplier Cat. no
Polyclonal goat anti-rabbit immunoglobulin/HRP 1:2000 TBS-T 5% milk (Wb) Dako P0447
Polyclonal goat anti-mouse immunoglobulin/HRP 1:2000 TBS-T 5% milk (Wb) Dako P0448
Alexa Fluor 488 goat anti-mouse IgG H+L 1:1000 IF-buffer (IF) Invitrogen A11001
Alexa Fluor 488 goat anti-rabbit IgG H+L 1:1000 IF-buffer (IF) Invitrogen A11034
4.6. Immunofluorescence Staining
For immunofluorescence staining, cells were fixed in 4% PFA after 48 h of alpelisib treatment.
Cells were permeabilized and blocked in IF-buffer (DPBS + 5% BSA + 0.3% Tween20) for 1 h at RT and
stained with pS6 or Ki-67 primary antibodies over night at 4 ◦C (Table 2). Cells were washed three
times with IF-buffer and incubated with secondary antibodies (Invitrogen; Thermo Fisher Scientifc, Inc.,
Waltham, MA, USA) for 2 h at RT in the dark. We took microscope images using the EVOS FL Auto
2 Cell Imaging System (Invitrogen; Thermo Fisher Scientific, Inc., Waltham, MA, USA). Counting of
nuclei (DAPI channel) and pS6/Ki-67 positive cells (GFP channel) was performed using the Celleste
Image Analysis Software (Thermo Fisher Scientific).
4.7. Reverse Transcription Quantitative PCR (RT-qPCR)
For transcriptional analysis, we seeded 5000 cells/cm2 in culture medium and extracted mRNA
after 24 h of treatment with 10 µM alpelisib or solvent control. For transcriptional analysis on
differentiation, cells were seeded at a density of 13,000 cells/cm2. Cells were kept in differentiation
medium with or without 10 µM alpelisib for 10 days before RNA was extracted. RNA extraction,
reverse transcription, and qPCR were performed as previously described [18]. Table 3 contains a list of
primers used for qPCR assays (Applied Biosystems; Thermo Fisher Scientifc, Inc.). Glucose transporter
1 (GLUT1), phosphoglycerate kinase (PGK), and Proliferating cell nuclear antigen (PCNA) mRNA was
normalized to the housekeeper Tata box binding protein (TBP) mRNA. PPARγ, adiponectin, aP2, FASN,
p16, CD44, and CD90 mRNA were normalized to the housekeepers β-actin or HPRT mRNA.
Table 3. Primers used for RT-qPCR.
Gene Forward Reverse Probe
TBP TTGTAAACTTGACCTAAAGACCATTGC TTCGTGGCTCTCTTATCCTCATG AACGCCGAATATAATCCCAAGCGGTTTG
β-actin CGA GCG CGG CTA CAG CTT TGC TTG TGT TGG GTG GAT ATT G TGG CCA CCG ACT CCT ACA AGG TTA CTC AC
HPRT GGC AGT ATA ATC CAA AGA TGG TCA A GTC TGG CTT ATA TCC AAC ACT TCG T CAA GCT TGC TGG TGA AAA GGA CCC C
GLUT1 TGGCATCAACGCTGTCTTCT AGCCAATGGTGGCATACACA
PGK GAATGGGAAGCTTTTGCCCG GCAGTGTCTCCACCACCTATG
PCNA CTAAAATGCGCCGGCAATGA TCTCCTGGTTTGGTGCTTCA
Adiponectin GGC CGT GAT GGC AGA GAT CCT TCA GCC CCG GGT ACT CGATGTCTCCCTTAGGACCAATAAGACCTGG
aP2 GCTTTTGTAGGTACCTGGAAACTTG ACA CTG ATG ATC ATG TTA GGT TTG G CCTGGTGGCAAAGCCCACTCCTCAT
PPARγ GATCCAGTGGTTGCAGATTACAA GAGGGAGTTGGAAGGCTCTTC TGACCTGAAACTTCAAGAGTACCAAAGTGCAA
FASN GGCAAATTCGACCTTTCTCAGA GGACCCCGTGGAATGTCA CACCCGCTCGGCATGGCTATCTT
p16 CTTCGGCTGACTGGCTGG TCATCATGACCTGGATCGGC
CD44 Predesigned assay (ID: Hs01075864_m1)
CD90 Predesigned assay (ID: Hs00264235_s1)
4.8. Senescence β-Galactosidase Staining
To detect senescence, we seeded 2000 cells/well on 96-well plates in culture medium. After 72 h of
treatment with 10 µM alpelisib or solvent control, we performed fixation and senescent cell staining
using the Senescence β-Galactosidase Staining Kit (Cell Signaling Technology, Inc., Danvers, MA, USA)
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according to the manufacturer’s protocol. We used 60 µl β-galactosidase staining solution per well
and after overnight incubation, we added 50 µL Hoechst in DPBS (1 ng/mL) and took microscope
images using the EVOS FL Auto 2 Cell Imaging System (pictures of 5% of the well area). We counted
nuclei (DAPI channel) with the Celleste Image Analysis Software (Thermo Fisher Scientific) and
β-galactosidase positive cells (blue, phase contrast) using ImageJ [33].
4.9. Statistical Analysis
Means of at least three independent experiments were statistically analyzed using GraphPad
Prism 6 software (GraphPad Software, Inc., La Jolla, CA, USA). For comparison of two conditions,
means of independent experiments were compared via unpaired Student’s t-test. For multiple
comparisons, we used one- or two-way analysis of variance (ANOVA), followed by a post-hoc
Tukey’s multiple comparisons test (one-way ANOVA) or Dunnett’s multiple comparisons test
(two-way ANOVA). To determine the significance of fold changes, we used one-sample t-tests
of the log(fold change) and compared to the hypothetical value 0 [34]. To calculate IC50 values, we used
GraphPad Prism 6 (nonlinear fit, log(inhibitor) vs. response, least squares fit, standard slope model).
Isobologram analysis [13] was done using the CalcuSyn software program.
5. Conclusions
Lipomatosis in pediatric PHTS patients is a rare condition, but nevertheless, can affect individuals
in a life-threatening manner due to limited treatment options. In this research project, we tested the
PI3K inhibitor alpelisib on PTEN-haploinsufficient lipoma cells from PHTS patients. We found that
alpelisib inhibited cellular growth and reduced the size of 3D lipoma cell cultures, although alpelisib
did not induce apoptosis. In contrast to rapamycin, alpelisib inhibited activation of AKT, promising to
overcome drug resistance mechanisms occurring during rapamycin treatment in PHTS patients [4].
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